Mesoblast (NASDAQ:MESO) Shares Gap Down – Should You Sell?

Mesoblast Limited (NASDAQ:MESO) shares gapped down prior to trading on Tuesday . The stock had previously closed at $14.87, but opened at $13.88. Mesoblast shares last traded at $13.7960, with a volume of 101,995 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mesoblast in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold”.

Mesoblast Stock Performance

The firm’s fifty day moving average price is $15.97 and its 200-day moving average price is $16.88. The company has a current ratio of 1.58, a quick ratio of 1.41 and a debt-to-equity ratio of 0.10. The company has a market cap of $1.74 billion, a P/E ratio of -15.37 and a beta of 2.19.

Mesoblast (NASDAQ:MESO) last posted its quarterly earnings data on Thursday, January 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $25.67 million for the quarter. As a group, research analysts forecast that Mesoblast Limited will post -0.7 EPS for the current fiscal year.

Institutional Trading of Mesoblast

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MESO. Caitong International Asset Management Co. Ltd bought a new stake in Mesoblast in the fourth quarter valued at about $32,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Mesoblast by 30.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,383 shares of the company’s stock valued at $43,000 after acquiring an additional 558 shares during the period. JPMorgan Chase & Co. increased its stake in Mesoblast by 55.6% in the third quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company’s stock valued at $46,000 after acquiring an additional 1,012 shares during the period. JFS Wealth Advisors LLC bought a new stake in Mesoblast in the third quarter valued at about $54,000. Finally, Farther Finance Advisors LLC bought a new stake in Mesoblast in the third quarter valued at about $58,000. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.